Our current study demonstrates that the 7HP349 effect promotes CXCL12-dependent immune cell sequestration at the TME, which could represent a new means of enhancing T cell homing that could be combined with immunotherapy strategies, such as checkpoint blockade and cancer vaccines in a T cell–noninflamed “cold” TME (4). The gene discussed is CXCL12; the disease is cancer.